Literature DB >> 19912592

Therapeutic efficacy of chloroquine and sequence variation in pfcrt gene among patients with falciparum malaria in central India.

Praveen Kumar Bharti1, Mohammad Tauqeer Alam, Robert Boxer, Man Mohan Shukla, Sant P Gautam, Yagya D Sharma, Neeru Singh.   

Abstract

OBJECTIVES: To assess the therapeutic efficacy of chloroquine (CQ) treatment against uncomplicated Plasmodium falciparum infections in a tribal population of central India (Madhya Pradesh) and to investigate the prevalence of mutant P. falciparum chloroquine-resistant transporter (pfcrt) gene in the parasite population.
METHODS: Clinical and parasitological response was determined by in-vivo testing. For molecular testing, the parasite DNA was extracted from blood samples and used to amplify and sequence parts of the pfcrt (44-177 codons), MSP1 (block 2) and MSP2 (central repeat region) genes.
RESULTS: Of 463 patients presenting fever, 137 tested positive for P. falciparum. They were treated with CQ. Of these, 58% participated in the study. Overall, treatment failure occurred in 53% of participants. Children under 5 years of age showed significantly more CQ resistance than adults. Mutant genotype S(72)V(73)M(74)N(75)T(76) was prevalent among both CQ responders (61.29%) and non-responders (66.7%). Interestingly, several patients from the CQ non-responder group (33.3%, n = 39) were harbouring parasite with wild type C(72)V(73)M(74)N(75)K(76) genotype of the pfcrt gene. Microsatellite sequences downstream of exon 2 varied widely among both wild type and mutant pfcrt haplotypes.
CONCLUSION: The high rate of treatment failure in the present study clearly indicates the need to reassess the use of CQ as first-line antimalarial therapy in central India. This is supported by the presence of mutant pfcrt genotype among majority of the parasite population of the CQ non-responder group of patients. However, the presence of wild type amino acid at codon 76 of the pfcrt gene among several patients with CQ non-responders requires further investigations.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19912592     DOI: 10.1111/j.1365-3156.2009.02425.x

Source DB:  PubMed          Journal:  Trop Med Int Health        ISSN: 1360-2276            Impact factor:   2.622


  16 in total

1.  Therapeutic efficacy of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in four malaria endemic states of India.

Authors:  Sri Krishna; Sweta Mishra; Prakash Tiwari; Anup K Vishwakarma; Sushrikanta Khandai; Suyesh Shrivastava; Anil K Verma; Shashikant Tiwari; Hari Barman; Surendra Jhariya; Pradeep Tiwari; Anup S Tidgam; Brij M Varun; Sunil Singh; Naresh Yerane; Chintaman R Tembhurne; Prem L Mandavi; Shyam S Tekam; Manas Malik; Kali P Behera; Himanshu Jayswar; Khemraj Sonwani; Mukund S Diggikar; Madan M Pradhan; Sher S Khasotiya; Avdhesh Kumar; Neeraj Dhingra; Maria Dorina G Bustos; Eva-Maria Christophel; Pascal Ringwald; Roop Kumari; Man M Shukla; Neeru Singh; Aparup Das; Praveen K Bharti
Journal:  Malar J       Date:  2021-05-21       Impact factor: 2.979

2.  Evidence of selective sweeps in genes conferring resistance to chloroquine and pyrimethamine in Plasmodium falciparum isolates in India.

Authors:  Tonya Mixson-Hayden; Vidhan Jain; Andrea M McCollum; Amanda Poe; Avinash C Nagpal; Aditya P Dash; Jonathan K Stiles; Venkatachalam Udhayakumar; Neeru Singh
Journal:  Antimicrob Agents Chemother       Date:  2009-12-28       Impact factor: 5.191

3.  Clinical and molecular monitoring of Plasmodium falciparum resistance to antimalarial drug (artesunate+sulphadoxine-pyrimethamine) in two highly malarious district of Madhya Pradesh, Central India from 2012-2014.

Authors:  Sweta Mishra; Praveen K Bharti; Man M Shukla; Nazia A Ali; Sher S Kashyotia; Avdhesh Kumar; Akshay C Dhariwal; Neeru Singh
Journal:  Pathog Glob Health       Date:  2017-05-26       Impact factor: 2.894

Review 4.  Malaria drug resistance: new observations and developments.

Authors:  Juliana M Sá; Jason L Chong; Thomas E Wellems
Journal:  Essays Biochem       Date:  2011       Impact factor: 8.000

5.  Field and laboratory comparative evaluation of rapid malaria diagnostic tests versus traditional and molecular techniques in India.

Authors:  Neeru Singh; Man M Shukla; Mohan K Shukla; Rajiv K Mehra; Shweta Sharma; Praveen K Bharti; Mrigendra P Singh; Ajay Singh; Arunachalam Gunasekar
Journal:  Malar J       Date:  2010-07-05       Impact factor: 2.979

6.  Double mutation in the pfmdr1 gene is associated with emergence of chloroquine-resistant Plasmodium falciparum malaria in Eastern India.

Authors:  Sabyasachi Das; Santanu Kar Mahapatra; Satyajit Tripathy; Sourav Chattopadhyay; Sandeep Kumar Dash; Debasis Mandal; Balaram Das; Amiya Kumar Hati; Somenath Roy
Journal:  Antimicrob Agents Chemother       Date:  2014-07-28       Impact factor: 5.191

7.  Antibodies to malaria vaccine candidates are associated with chloroquine or sulphadoxine/pyrimethamine treatment efficacy in children in an endemic area of Burkina Faso.

Authors:  Amidou Diarra; Issa Nebie; Alfred Tiono; Issiaka Soulama; Alphonse Ouedraogo; Amadou Konate; Michael Theisen; Daniel Dodoo; Alfred Traore; Sodiomon B Sirima
Journal:  Malar J       Date:  2012-03-22       Impact factor: 2.979

8.  Genetic diversity in the block 2 region of the merozoite surface protein-1 of Plasmodium falciparum in central India.

Authors:  Praveen K Bharti; Man M Shukla; Yagya D Sharma; Neeru Singh
Journal:  Malar J       Date:  2012-03-22       Impact factor: 2.979

9.  Establishing communication mechanism for malaria prevention in Baiga tribal villages in Baiga Chak area of Dindori district, Madhya Pradesh.

Authors:  Kalyan B Saha; Ravendra K Sharma; Rajdeep Mishra; Arvind Verma; B K Tiwari; Neeru Singh
Journal:  Indian J Med Res       Date:  2015-05       Impact factor: 2.375

10.  Transmission dynamics & epidemiology of malaria in two tribal districts in Madhya Pradesh, India.

Authors:  Gyan Chand; N K Chaudhary; V Soan; L S Kaushal; R K Sharma; Neeru Singh
Journal:  Indian J Med Res       Date:  2015-05       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.